top of page

NCI-2022-09157

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO) Her2 Radiation Optimization (HERO)


This is a Phase III randomized research study that is comparing radiotherapy optimization for low-risk HER2-positive breast cancer. It is investigating whether radiotherapy can be omitted for certain patients with low-risk HER2-positive breast cancer who are also receiving HER2-targeted therapy. The goal of the trial is to see if omitting radiation therapy is safe and effective for patients that could potentially reduce treatment burden and side effects for some patients.


HER-2 Positive: It is a type of breast cancer where cancer cells have higher-than-normal levels of HER-2 receptors are called HER-2 positive. These receptors are like tiny doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain drugs that target the HER-2 receptor.

Radiotherapy: Radiotherapy to the whole breast/chest area and the surrounding lymph glands is called regional radiotherapy.

Phase III: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

Randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment


For more information about the trial, click the link below:

NCI-2022-09157

Clinical Trial Site: Einstein/Columbia


To see all available clinical trials click here. 



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CAR

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatoce

Comentarios


bottom of page